BPC-157 Peptide Therapy 

​

• USA-sourced product

•  COA available

• Doctor-supervised at Revival Clinic Bangkok

​

BPC-157 (Body Protection Compound-157) is a synthetic peptide studied for its potential role in tissue repair and recovery. At our clinic, BPC-157 is provided as a 5 mg vial, with quality documentation (COA) and is administered under medical supervision to support patient safety and proper technique.

Important: Research on BPC-157 in humans is limited. Much of the available evidence comes from preclinical (animal/lab) studies and reviews, and BPC-157 is considered investigational in many settings. 

​

Why our clinic

• USA product + COA: We use USA-sourced BPC-157 and provide a Certificate of Analysis (COA) for transparency and quality assurance.

• Doctor-supervised care: Your treatment plan and follow-up are overseen by clinicians to help reduce risks from incorrect dosing, contamination, or poor injection technique.

• Affordable, complete kit: We provide the full injection set (vial + sterile water + insulin syringes/needles + alcohol swabs + written instructions). Additional injection sets are available if needed.

​

BPC-157  benefits

BPC-157 has been studied for potential effects related to:

• Soft-tissue recovery support (tendons/ligaments/muscles) and tissue repair processes in preclinical models 

• Gut and digestive support, as BPC-157 is derived from a peptide sequence associated with gastric tissue and has been explored in gastrointestinal research contexts (mostly preclinical/review data) 

​

Our clinic protocol (5 mg vial)

Product format

• BPC-157: 5 mg vial

• Reconstitution volume: 1 mL sterile water per vial

• Administration: Subcutaneous injection using an insulin syringe

• Inject 0.2 ml ( 1 mg ) once daily with an insulin syringe
   

How to prepare & inject 

1) Reconstitute (one time per vial)

Inject 1 ml sterile water into the BPC-157 vial using a syringe. Gently swirl until clear. Do not shake. Label the vial with the mixing date.

2) Daily injection (subcutaneous)

Using an insulin syringe, draw 20 units and inject subcutaneously as instructed by your healthcare provider. Rotate injection sites to reduce irritation.

3) Storage

Store the mixed vial in the refrigerator (2–8°C) and use only as directed.

​

Possible side effects

Side effects can vary and may include:

• Injection-site irritation (redness, tenderness, swelling)

• Headache, fatigue, or dizziness (reported anecdotally/observationally)

• Digestive discomfort in some individuals

​

Contraindications & precautions

BPC-157 may not be appropriate for everyone.

Do not use or seek medical advice first if you have:

• Pregnancy or breastfeeding

• Known allergy to any component

• Active cancer or undergoing cancer treatment 

• Significant uncontrolled medical conditions

If you are a competitive athlete, note that BPC-157 is listed under WADA Prohibited List (S0: Non-approved substances) and is prohibited in sport. 

​

Drug interactions

There is no well-established interaction profile for BPC-157 in humans due to limited clinical data. Please tell your doctor if you use:

• Blood thinners / antiplatelets

• Steroids or immunosuppressants

• Diabetes medications

• Any injectable therapies or “peptide stacks”

​

Common questions (FAQ)

​

What is a COA?

A Certificate of Analysis (COA) is a lab document that reports key quality checks (e.g., identity/purity testing) for a batch. We provide COA documentation for transparency.

​

Do you provide supplies?

Yes. We prepare a complete kit (vial + sterile water + syringes/needles + alcohol swabs + instructions). You can purchase additional injection sets if needed.

​

References 

1. Vasireddi N, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine (systematic review; notes lack of clinical safety data). 

2. McGuire FP, et al. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing (review; mainly preclinical evidence). 

3. Chang CH, et al. Promoting effect of BPC-157 on tendon healing (preclinical tendon study). 

4. FDA: Certain Bulk Drug Substances for Use in Compounding—may present significant safety risks (includes BPC-157; limited safety information/concerns). 

5. World Anti-Doping Agency (WADA): Prohibited List (includes BPC-157 as an example under S0 in current lists). 

6. USADA: BPC-157 educational notice (prohibited under WADA; not approved for human clinical use).